Institute of Orthopedic Surgery, Xijing Hospital, Fourth Military Medical University, Xi’an, China, Lingbo Kong1

Particle-Induced Osteolysis in Mice

Pyrroloquinoline Quinine Inhibits RANKL-Mediated Expression of NFATc1 in Part via Suppression of c-Fos in Mouse Bone Marrow Cells and Inhibits Wear Particle-Induced Osteolysis in Mice

Lingbo Kong1, Chongfei Yang1, Lifeng Yu1, Wanli Smith2, Shu Zhu1, Jinyu Zhu1, Qingsheng Zhu1*

1 Institute of Orthopedic Surgery, Xijing Hospital, Fourth Military Medical University, Xi’an, China, 2 Department of Pharmaceutical Sciences, University of Maryland School of Pharmacy, Baltimore, Maryland, United States of America

Abstract

The effects of pyrroloquinoline quinine (PQQ) on RANKL-induced osteoclast differentiation and on wear particle-induced osteolysis were examined in this study. PQQ inhibited RANKL-mediated osteoclast differentiation in bone marrow macrophages (BMMs) in a dose-dependent manner without any evidence of cytotoxicity. The mRNA expression of c-Fos, NFATc1, and TRAP in RANKL-treated BMMs was inhibited by PQQ treatment. Moreover, RANKL-induced c-Fos and NFATc1 protein expression was suppressed by PQQ. PQQ additionally inhibited the bone resorptive activity of differentiated osteoclasts. Further a UHMWPE-induced murine calvaria erosion model study was performed to assess the effects of PQQ on wear particle-induced osteolysis in vivo. Mice treated with PQQ demonstrated marked attenuation of bone erosion based on Micro-CT and histologic analysis of calvaria. These results collectively suggested that PQQ demonstrated inhibitory effects on osteoclast differentiation in vitro and may suppress wear particle-induced osteolysis in vivo, indicating that PQQ may therefore serve as a useful drug in the prevention of bone loss.

Citation: Kong L, Yang C, Yu L, Smith W, Zhu S, et al. (2013) Pyrroloquinoline Quinine Inhibits RANKL-Mediated Expression of NFATc1 in Part via Suppression of c-Fos in Mouse Bone Marrow Cells and Inhibits Wear Particle-Induced Osteolysis in Mice. PLoS ONE 8(4): e61013. doi:10.1371/journal.pone.0061013

Editor: Johnny Huard, University of Pittsburgh, United States of America

Received December 6, 2012; Accepted March 5, 2013; Published April 17, 2013

Copyright: © 2013 Kong et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: This work was supported in part by a grant-in-aid for scientific research from the Fourth Military Medical University. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

* E-mail: qingshengzhu@hotmail.co.uk

† These authors contributed equally to this work.

Introduction

Destructive erosion of bone or osteolysis is a major complication of inflammatory conditions such as rheumatoid arthritis (RA), periodontal disease, and periprosthetic osteolysis [1]. Periprosthetic osteolysis is caused by chronic bone resorption around exogenous implant devices until fixation is lost [2], and is considered as resulting from an innate immune response to wear-debris particles, with little contribution by components of the acquired immune system [3]. There is extremely strong evidence that the biological response to particulate ultra-high molecular weight polyethylene (UHMWPE) wear debris generated primarily at the articulating interface is the key factor in the development of osteolysis [3,4]. The UHMWPE wear particles enter the peri-prosthetic tissue where they are phagocytosed by macrophages. The macrophages then release an array of cytokines and other mediators of inflammation that lead to the development of an inflamed granulomatous tissue adjacent to the bone. Eventually, osteoclasts are recruited and/or activated to resorb the bone leading to osteolysis and finally loosening of the prosthesis [4].

Osteoclasts are multinucleated giant cells that originate from the hematopoietic stem cell monocyte/macrophage lineage [5]. Osteoclasts differentiate into multinucleated giant cells that attach to bone tissue and excrete various types of acids and enzymes. Osteoblasts and stromal cells express receptor activator of the nuclear factor-κB (NF-κB) ligand (RANKL) and macrophage colony-stimulating factor (M-CSF) [6]. M-CSF provides survival signals to osteoclasts and their precursor cells. RANKL is a member of the tumor necrosis factor (TNF) family and binds to the RANK receptor expressed in osteoclast precursor cells [7]. The binding of RANKL and RANK on osteoclast progenitor cells triggers the activation of tumor necrosis factor receptor-associated factor 6 (TRAF6) [8] and subsequently the activation of NF-κB and mitogen-activated protein kinases (MAPKs), such as extracellular signal-regulated kinase 1/2 (ERK1/2), p38 and stress-activated protein kinase/c-Jun N-terminal kinase (SAPK/JNK) [9,10]. Nuclear factor of activated T cells (NFATc1) is a downstream transcription factor in the RANKL/RANK signal pathway and as a key molecule of osteoclastogenesis, NFATc1 induces a series of osteoclast-specific genes, including cathepsin K, tartrate-resistant acid phosphatase (TRAP), calcitonin receptor and osteoclast-associated receptor [11,12]. c-Fos is also an essential transcription factor for osteoclastogenesis and upregulates osteoclastogenesis via NFATc1 activation [13].

Pyrroloquinoline quinine (PQQ) possesses a variety of functions ranging from classical vitamin to anti- and pro-oxidant [14]. Recently, PQQ has been reported to regulate several intracellular signaling pathways, including Ras-related
Materials and Methods

Ultra High Molecular Weight Polyethylene Particles

UHMWPE particles were provided by Mr. Ernst Krendlinger, the manufacturer of Clariant, Gersthofen, Germany. Scanning electron microscopy (Hitachi, Osaka, Japan) analysis demonstrated that 90% of the UHMWPE particles were less than 9 μm in diameter, with a mean size of 1.74 μm, with diameters ranging from less than 0.05 to 11.06 μm (SD 1.43μm). The sizes of most particles are in the biologically active range compared with isolated periprosthetic membrane [19]. UHMWPE particles were washed in 70% ethanol solution at room temperature using a rocking device to remove endotoxin, and resuspended in sterile phosphate-buffered saline (PBS) at a concentration of 100 mg/ml, and stored at 4°C until use [20,21]. The particle suspension was determined to be endotoxin free by the Limulus assay (Sigma-Aldrich, St. Louis, MO, USA).

Cell Culture

Pyrroloquinoline quinine (PQQ) disodium salt was purchased from Wako (Wako Pure Chemical Industries, Ltd. Osaka, Japan). Bone marrow cells were obtained by flushing the femurs and tibiae of 5–7 days old Sprague-Dawley rats [22]. After euthanasia in CO2 chamber, the rats were sterilized in 75% ethanol for 10 min. The long bones were taken out, and the soft tissues attached to the bones were removed. The bones were minced and rinsed in α-MEM. The cells were dissociated and collected from the bone fragments. Cells were then centrifuged (1500 g for 10 min). The cells were used as un fractionated bone cells and were resuspended in α-MEM containing 10% fetal bovine serum (FBS) with 1% penicillin and streptomycin (GIBCO; Invitrogen Corp, Carlsbad, CA, USA). Non-adherent cells were collected and cultured for 3 days in the presence of M-CSF (30 ng/ml). Floating cells were discarded and adherent cells on dish bottoms were classified as bone marrow derived macrophages (BMMs). BMMs were seeded at a density of 3.5×10^5 cells/well in α-MEM/10% FBS, and were cultured in the presence of M-CSF (50 ng/ml) and RANKL (50 ng/ml) for 4 days with or without PQQ [5]. Osteoclasts were identified by staining for tartrate-resistant acid phosphatase (TRAP) activity. TRAP-positive multinucleated cells with more than three nuclei were counted as osteoclasts.

Cytotoxicity Assay for PQQ

BMMs were seeded in 96-well plates at a density of 1×10^4 cells/well in triplicate. Cells were treated with M-CSF (30 ng/ml) and increasing concentrations of PQQ were added to the mix. Cells were incubated for 3 days. After 3 days, XTT reagent (50 μl) was added to each well. Wells were incubated for 4 hrs. The optical density at 450 nm was analyzed with an ELISA reader.

Clonogenic Assay

RAW 264.7 cells were seeded in 48-well plates at a density of 5,000 cells/well in triplicate and cultured for 4 days in the presence of increasing concentrations of PQQ. After 4 days, the cells were fixed and stained with Hematoxylin (Sigma, St. Louis, MO, USA). Colonies with 50 or greater cells were counted.

Real Time RT-PCR Analysis for c-Fos, NFATc1, and TRAP

Total RNA was isolated with TRIzol reagent (Invitrogen Inc., USA) following the manufacturer’s instructions. RNA (1 μg) was reverse transcribed using oligo dT primers (10 μg) and dNTPs (10 mM). The mixture was incubated at 65°C for 5 min, and cDNA was produced by incubating at 42°C for 30 min with first strand buffer (50 mM Tris–HCl, pH 8.3, 75 mM KCl, 3 mM MgCl2), 100 mM DTT, RNase inhibitor, and Superscript II reverse transcriptase (Invitrogen Inc., USA). The cDNA was amplified using the following primer sets: c-Fos, 5’-CTGTGAGCCAGGGACTCTGTCGTC-3’ (forward) and 5’-GCTGGACAGTTCATCTGTC-3’ (reverse); NFATc1, 5’-CTTGGAAAGCTTCAATCTCAGACGCTGATGCCAGCGACA-3’ (forward) and 5’-CGATGGACCAGA-3’ (reverse); TRAP, 5’-CTGAGTGCGACAGTGGCCAGGACA-3’ (forward) and 5’-TCCGGTTCGGCTGGCAGTGAGACCAGCA-3’ (reverse). PCR was performed using the QuantitectSYBR Green PCR kit (QIagen, USA) in triplicates according to the manufacturer’s instructions. Relative levels of c-Fos, NFATc1, and TRAP were normalized to GAPDH.

Western Blot Analysis

Cells were lysed in a buffer containing 50 mM Tris–HCl, 150 mM NaCl, 5 mM EDTA, 1% Triton X-100, 1 mM sodium fluoride, 1 mM sodium vanadate, 1% deoxycholate, and protease inhibitors. The lysates were centrifuged at 14,000×g for 20 min and supernatants were collected. Protein concentrations of supernatants were determined. Cellular proteins (30 μg) were resolved by 8–10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and were transferred to polyvinylidene difluoride membranes (Millipore, Bedford, MA, USA). Non-specific interactions were blocked with 5% skim milk for 2 h and were then probed with the appropriate primary antibodies. Membranes were incubated with the appropriate secondary antibodies attached to horseradish peroxidase, and immunoreactivity was detected with enhanced chemiluminescence reagents.

Animal Experiments

A murine calvarial model of UHMWPE particle-induced osteolysis was used in this study [23,24]. All the animal work and approach have been approved by the IACUC of the Fourth Military Medical University and conducted strictly followed by “the institutional guidelines for the care and use of laboratory animals at the Fourth Military Medical University.” 48 healthy C57BL/6J mice aged 6–8 wk with a mean weight of 21.25±1.2 g (20.4–22.1 g) were randomly divided into four groups: (1) the PBS group (sham control group), (2) the UHMWPE group, where the mice received 30 mg of UHMWPE particles implantation, (3) the UHMWPE+PQQ1 group, where the mice received 30 mg of UHMWPE particles plus 1 mg/kg of PQQ intraperitoneal injection every day from d1 to d14, and (4) the UHMWPE+PQQ10 group, where the mice received 30 mg of UHMWPE particles plus 10 mg/kg of PQQ intraperitoneal injection every day from d1 to d14. The animals had free access to water and food and were kept in a 12 h on/12 h off specific pathogen-free animal room. Each
mouse was anesthetized with an intraperitoneal injection of pentobarbital. Under sterile conditions, a longitudinal incision was made on the scalp between the two external ears, and the external cranial periosteum was exposed. The periosteum was removed until coronal, sagittal, and lambdoid sutures of the calvariae were visible. A total amount of 30 mg of UHMWPE particles in 300 μL PBS was applied on the surface of the calvariae. The skin was closed with simple interrupted suture to prevent leakage of the particles. In the PBS group, the animals underwent operation with 300 μL sterile PBS without particles. After the operation, the mice were warmed up, recovered, and sent back to the animal room. No complications occurred. All wounds healed uneventfully. Two weeks after the operation, the animals were killed in a CO₂ chamber. The specimens freed of soft tissue and underlying brain were fixed in 10% paraformaldehyde.

Micro Computed Tomography Analyses
High resolution in vivo micro computed tomography (Explore Locus SP; GE Healthcare, Madison, WI) of calvarial bone structure was performed on paraformaldehyde fixed dissected samples of six mice in each group before histological analysis. The X-ray source was set at a voltage of 80 kV and a current of 80 μA using an integration time of 3000 ms. The skulls were scanned with isometric resolution of 14 μm. A region of interest (ROI) defined by the operator as the largest osteolytic volume, which fits in a 152×152×152 voxel template (85.2 mm³) [25]. MicroView ABA ver. 2.1.2 software of GE Healthcare was used to analyze data, and bone mineral density (BMD), bone volume fraction (BVF), cortical mean thickness (CMT), and cortical area/total area (Ct) were applied to measure UHMWPE-fraction (BVF), cortical mean thickness (CMT), and cortical area/total area (Ct) were applied to measure UHMWPE-induced osteolysis.

Histologic Analysis
The harvest samples were decalcified in 14% EDTA, dehydrated in graded alcohols, and embedded in paraffin. Each specimen was sectioned to a thickness of 4 μm on the sagittal plane at 2 mm lateral to the midsagittal suture. Each section was sampled twice, 150 μm apart, producing four sections per animal. The sections were stained with hematoxylin and eosin (HE) or TRAP. The sections stained with HE or with TRAP were examined under light microscopy (DMLA; Leica, Wetzlar, Germany). Histomorphometric analysis was performed using QWin V3.1 software (Leica, Germany). The coronal suture area in the HE-stained sections was determined by tracing the area of soft tissue between the parietal bones, including any resorption pits on the superior surface of the calvariae visible in the same field, and was quantified by the modified method described by Childs [26] et al. The number of osteoclasts was counted in the TRAP stained sections. The results from the four sections for each animal were averaged, and the average coronal suture area and the number of osteoclast for each group of animals were calculated [27].

Statistical Analysis
All data are expressed as means ± standard deviation (SD). Statistical analysis was done using SPSS software package ver. 11.0 (SPSS, Chicago, IL); one-way ANOVA was used for comparison among the different groups. Post hoc testing of differences between groups was performed by using Duncan’s test when the ANOVA was significant. Statistical significance was defined at p values <0.05 (p<0.05).

Results

Inhibition of Osteoclast Differentiation by PQQ
Osteoclasts were generated from mouse BMMs in the presence of M-CSF (30 ng/ml) plus RANKL (50 ng/ml) to verify the effects of PQQ in osteoclastogenesis. The BMMs of the control group differentiated into mature TRAP-positive multinucleated osteoclasts while PQQ reduced the formation and numbers of TRAP-positive multinucleated cells in a dose-dependent manner (Fig. 1A; Fig. 1B).

The Cytotoxic Effect of PQQ
PQQ generated a highly negative effect on osteoclastogenesis. We measured the effects of PQQ on bone marrow cells with the XTT assay to exclude the possibility that the inhibition was due to cytotoxicity. PQQ demonstrated no cytotoxic effects at the same doses which effectively inhibited osteoclast formation (Fig. 1C). Also, PQQ did not affect in RAW 264.7 cells colony formation (Fig. 1D), suggesting that osteoclastogenesis suppression by PQQ was not due to toxic effects on BMMs.

RANKL Induced c-Fos, NFATc1 and TRAP mRNA Expression is Reduced by PQQ
Osteoclast differentiation is regulated by the induction of various genes in response to RANKL and RANK binding [5]. The c-Fos and NFATc1 genes have an essential role in the osteoclast differentiation [28]. We examined the effects of PQQ on the RANKL-induced regulation of c-Fos and NFATc1 expression, and to assess whether there were any effects on TRAP expression. Osteoclast precursors were pretreated with PQQ and further stimulated with RANKL for various periods (12 hrs, 24 hrs and 48 hrs). Results revealed that c-Fos and NFATc1 mRNA levels were increased in response to RANKL, but both c-Fos and NFATc1 expression was significantly inhibited by PQQ (Fig. 2A; Fig. 2B). TRAP mRNA expression was significantly inhibited by PQQ (Fig. 2C). This raises the possibility that, PQQ may inhibit osteoclast differentiation through the inhibition of RANKL-induced c-Fos and NFATc1 expression.

PQQ also Inhibits c-Fos and NFATc1 Protein Expression
Western blots were used to verify the effects of PQQ on c-Fos and NFATc1 protein expression. c-Fos and NFATc1 protein levels were increased in response to RANKL, but c-Fos and NFATc1 expression was significantly inhibited by PQQ (Fig. 2D). These results demonstrated that the inhibitory effects of PQQ involved the inhibition of major transcription factors such as c-Fos and NFATc1.

PQQ Inhibited Osteolysis Caused by Wear Particles in vivo
The murine calvarial osteolysis model was used to evaluate if PQQ would inhibit particle-induced osteolysis. The three-dimensional reconstruction of bone microarchitecture in the murine skull by micro-CT was shown in Fig. 3. In the UHMWPE group, the particle-induced osteolysis was apparent (Fig. 3B). In the PQQ groups, however, the particle-induced osteolysis was reduced compared with the UHMWPE group (Fig. 3C; Fig. 3D). The PBS group showed no pronounced osteolysis (Fig. 1C). Treatment with PQQ prevented the particle-induced effects on bone metabolism and bone micro-architecture in the murine skull. The quantification of bone changes in the murine skull was shown (Fig. 4; Table 1). Compared with the PBS group, the UHMWPE group showed a significant decrease in BMD, BVF, CMT, and Ct.
respectively. Treatment with PQQ (1 mg/kg) attenuated the UHMWPE particle-induced decrease in BMD, BVF, CMT, and Ct respectively. In a similar fashion, treatment with PQQ (10 mg/kg) significantly prevented the UHMWPE particle-induced decrease in BMD, BVF, CMT and Ct respectively (P < 0.05).

While both of the treatments increased BMD, BVF, CMT and Ct compared to the UHMWPE group, PQQ (10 mg/kg) group was found to exert greater effect on BMD, BVF, CMT, and Ct compared with PQQ (1 mg/kg) group.

PQQ Inhibited Osteoclastogenesis Caused by Wear Particles in vivo

Less inflammatory reaction and little resorption were observed in the PBS group (Fig. 5A: a, Fig. 5A: c). There was a pronounced inflammatory reaction with highly vascularized granulation containing macrophages and multinuclear giant cells in the UHMWPE group (Fig. 5A: b, Fig. 5A: f, Fig. 5A: i, Fig. 5A: j, Fig. 5A: k). Marked osteolysis was located adjacent to these inflammatory reaction tissues. The bone volume of murine calvarium was reduced extensively by osteolysis in this group. In the PQQ (1 and 10 mg/kg) treated groups, bone destruction and resorption were less than that of the UHMWPE group but were more pronounced than that of the PBS group (Fig. 5A: c, Fig. 5A: g, Fig. 5A: d, Fig. 5A: h and Fig. 5A: l). The osteolysis area was quantitatively evaluated according to the coronal suture area including any visible resorption pits in each sample (Fig. 5B). In the PBS group, the osteolysis area was 0.0796 ± 0.0089 mm². The skull implanted with UHMWPE showed the greatest osteolysis area, 0.373 ± 0.0121 mm², which was significantly higher than that of the PBS group (P < 0.05). In the PQQ (1 and 10 mg/kg) treated groups, the osteolysis area was 0.223 ± 0.009 mm² and 0.13 ± 0.011 mm², respectively (P < 0.05). The TRAP-positive osteoclast number within the experimental areas in the PBS group was 6.081 ± 0.712. In the UHMWPE group, the number rose to 27.021 ± 2.071. In the PQQ (1 mg/kg) group, the number was 14.872 ± 1.802, while in the PQQ (10 mg/kg) group, it was 8.021 ± 1.002. There was a significant difference in the osteoclast number between the PBS and the UHMWPE groups (P < 0.01).

PQQ (1 and 10 mg/kg) treatment significantly suppressed osteoclastogenesis induced by UHMWPE particles (P < 0.05, Fig. 5C).
Figure 2. **PQQ suppresses the mRNA expression of c-Fos, NFATc1, and TRAP in BMMs treated with RANKL.** (A–C) BMMs were pretreated with or without PQQ (15 μM) for 1 h and with RANKL (100 ng/ml) for the indicated periods. The mRNA expression of the indicated genes was analyzed by real time RT-PCR. Data are presented as mean ± SD; 0: Blank Control; # p<0.05 vs. Blank Control; * p<0.05 vs. DMSO+RANKL. (D) PQQ inhibits the expression of c-Fos and NFATc1 induced by RANKL. BMMs were pretreated with or without PQQ (15 μM) for 1 h and were treated with RANKL (100 ng/ml) for the indicated periods. Cells were lysed in the lysis buffer, and lysates were analyzed by Western blotting with antibodies against c-Fos, NFATc1, and actin. The intensities of the protein bands were analyzed and normalized to actin. Similar results were obtained in at least 3 independent experiments.

doi:10.1371/journal.pone.0061013.g002

Figure 3. **PQQ Inhibited Osteolysis Caused by Wear Particles in vivo.** Micro-CT three-dimensional reconstruction images of bone resorption in mouse calvarium. (A) Sham control group, (B) UHMWPE, (C) UHMWPE+PQQ 1 mg/kg, (D) UHMWPE+PQQ 10 mg/kg. Arrow indicates the low signal bone resorption area.

doi:10.1371/journal.pone.0061013.g003
Discussion

Bone resorption by osteoclasts is frequently caused by excessive RANKL signaling which has been a valuable target for the treatment of pathological bone loss. RANKL activates a series of major intracellular signal transducing pathways including NF-κB, phosphoinositide 3 kinase (PI3K)-Akt, JNK, ERK, and p38 MAPK. Binding of RANKL-RANK activates transcription factor NFATc1 through intracellular TNF receptor associated factor 6 (TRAF6) and c-Fos signaling pathways [5–8]. NFATc1 is a master regulator of osteoclastogenesis which autoamplifies and conducts the expression of osteoclast specific genes such as activator protein-1 (AP-1), TRAP, calcitonin receptor, OSCAR, and cathepsin K [11]. c-Fos was reported to be critical for transcriptional activation

Table 1. Bone histomorphometry parameters after 14-day treatment with PQQ.

|       | Control          | UHMWPE                   | UHMWPE+PQQ (1 mg/kg) | UHMWPE+PQQ (10 mg/kg) |
|-------|------------------|--------------------------|----------------------|-----------------------|
| BMD (mg/cc) | 24.452±1.644     | 9.342±0.895*             | 14.453±0.546**       | 21.340±1.344**        |
| BVF    | 14.423±0.909     | 5.845±0.670*             | 8.342±0.932**        | 11.232±0.908**        |
| CMT (mm)| 0.392±0.014      | 0.150±0.021*             | 0.301±0.019**        | 0.365±0.023           |
| Ca/Ta  | 13.213±0.778     | 6.431±0.509*             | 8.423±0.783*        | 11.807±0.813**        |

Values are mean ± SD (n = 6).
*P<0.01 different from control group.
**P<0.05 different from control group.
&P<0.01 different from UHMWPE group.
@P<0.05 different from low dose PQQ group.
doi:10.1371/journal.pone.0061013.t001

Figure 4. Change of bone parameters of mice skull analyzed by micro-CT. (A) BMD, bone mineral density, (B) BVF, bone volume fraction, (C) CMT, cortical mean thickness, (D) Ct, cortical area/total area data are presented as mean ± SD (n = 6). Asterisk indicates a statistically significant difference (p<0.05), comparison between the two groups connected by the line.
doi:10.1371/journal.pone.0061013.g004

Pyrroloquinolinequinine Inhibit Osteolysis in Mice

PLOS ONE | www.plosone.org 6 April 2013 | Volume 8 | Issue 4 | e61013
Pyrroloquinolinequinine Inhibit Osteolysis in Mice

A

Control

UHMWPE

UHMWPE+PQQ (1mg/kg)

UHMWPE+PQQ (10mg/kg)

B

Area of Osteolysis (mm²)

C

TRAP+ Osteoclast Number

UHMWPE

PQQ

- - + + + + (mg/kg)

- - + + + + (mg/kg)
of NFATc1 in RANKL-induced osteoclastogenesis [8–10]. Putative c-Fos binding sites were mapped in the promoter region of NFATc1, and the NFATc1 expression was abolished in the osteoclast precursors lacking c-Fos [10]. More interestingly, osteoclastogenic activity of NFATc1 was enhanced by overexpression of c-Jun and c-Fos, but inhibited by either DN-c-Jun or DN-c-Fos, indicating that the partnership between c-Jun/c-Fos and the NFATc1 is crucial for osteoclastogenesis [8–10]. PQQ is a non-covalently bound prosthetic group in some bacterial dehydrogenases where it helps catalyze the oxidation of sugars and alcohols. This bacteriologically-synthesized quinone is a water-soluble and heat-stable molecule that reacts readily with nucleophiles such as amino acids, thiol and ammonia [14]. While the potential physiological role of PQQ in animals is unclear, it may be acting as an antioxidant. PQQ was shown to scavenge O$_2^-$ and HO$^-$ efficiently [29,30]. A variety of other in vitro effects of PQQ have been observed, such as inhibiting lipid peroxidation [31], protecting the isolated heart from reoxygenation injury [32], and increasing the production of nerve growth factor in cell lines [33]. In animal models, high doses of PQQ protected tissues against hypoxic/ischaemic injury [34], chemical agent-induced seizure [35], carrageenan-induced inflammation [30], liver damage caused by ethanol [36] or carbon tetrachloride and the mortality induced by endotoxin [37]. Our data suggested that PQQ decreased osteoclast formation compared to the RANKL- and M-CSF-treated control groups, and these phenomena did not result from PQQ's cytotoxic effects. Moreover our data suggested that suppression of RANKL-induced activation of c-Fos and NFATc1 by PQQ correlated with osteoclastogenesis inhibition. Additionally, mRNA levels of major osteoclast marker TRAP was also inhibited by PQQ. These findings were in agreement with a very recently study showing that PQQ directly affects osteoclast precursors and inhibits the osteoclast generation [18], demonstrating that PQQ inhibited RANKL-induced NF-kB activation and osteoclast formation, it could be expected that the down-regulation of NF-kB could also be a promising target for the reduction of RANKL-induced c-Fos and NFATc1 expression during osteolysis.

We used the wear particle-induced murine calvarial osteolysis model to study the effects of PQQ treating particle-induced osteoclastogenesis in vivo. When 30 mg of UHMWPE particles were implanted in the calvariae of C57BL/6j mice, we observed a pronounced inflammatory reaction with highly vascularized granululation containing macrophages, TRAP-positive multinuclear osteoclasts, and marked osteolysis located adjacent to these inflammatory reaction tissues. In the PQQ treated (1 and 10 mg/kg) groups, the inflammatory reaction, bone destruction, and resorption area were less than that of the UHMWPE group but were more pronounced than that of the PBS group.

To evaluate whether PQQ would inhibit particle-induced osteolysis in the murine calvarial osteolysis model, we used Micro-CT. In the UHMWPE group, particle-induced osteolysis was apparent compared with the PBS group, where there was no pronounced osteolysis. In the PQQ treated (1 and 10 mg/kg) groups, the particle-induced osteolysis was reduced compared with the UHMWPE group, indicating that treatment with PQQ prevented the particle-induced effects on bone metabolism and bone microarchitecture in the murine skull. The quantification of bone changes in the murine skull is shown in Figure 4. Compared with the PBS group, the UHMWPE group showed significant decrease in BMD, BVF, CMT, and Ct. The decreases in BMD, BVF, CMT, and Ct were associated with decreased bone formation and increased osteolysis according to Hefferan [38]. In this study, treatment with PQQ (1 mg/kg) attenuated the UHMWPE particle-induced decrease in BMD, BVF, CMT and Ct. In a similar fashion, treatment with PQQ (10 mg/kg) significantly prevented the UHMWPE particle-induced decrease in BMD, BVF, CMT, and Ct. Treatment with PQQ (10 mg/kg) also resulted in the improvement in BMD, BVF, CMT, and Ct compared with the PQQ (1 mg/kg) treated group. All of these results showed that PQQ could inhibit wear particle-induced bone loosening. Extensive pharmacologic evaluation of PQQ is required to fully determine its effects in the treatment of wear particle-induced prosthesis loosening.

In conclusion, we demonstrated the inhibitory effects of PQQ on osteoclastogenesis in primary precursor cells in the present study. Further, the in vivo efficacy of PQQ was confirmed with a murine calvarial model of particle-induced osteolysis. Our findings suggest that PQQ may represent a promising agent for the prevention and treatment of particle-induced osteolysis through regulating osteoclastogenesis.

Author Contributions
Conceived and designed the experiments: LK CY WS QZ. Performed the experiments: LK CY LY SZ JZ. Analyzed the data: LK CY LY SZ JZ. Contributed reagents/materials/analysis tools: LK CY JZ WS. Wrote the paper: LK CY QZ.

References
1. Wei S, Gene P (2008) Mechanisms modulating inflammatory osteolysis: A review with insights into therapeutic targets. Pathology Research and Practice 10: 695–706.

2. Harris WH (1995) The problem is osteolysis. Clin Orthop Relat Res 311: 46–53.

3. Goldring SR, Jasty MS, Roelke MS, Roux CE, Bruggaier FR, et al. (1986) Formation of a synovial-like membrane at the bone-cement interface. Its role in bone resorption and implant loosening after total hip replacement. Arthritis Rheum 29: 836–842.

4. Ingham E, Pfeifer J (2005) The role of macrophages in osteolysis of total joint replacement. Biomaterials 26: 1271–1286.

5. Kwak HB, Lee BK (2010) Inhibition of osteoclast differentiation and bone resorption by rotenone, through down-regulation of RANKL-induced c-Fos and NFATc1 expression. Bone 46: 724–731.

6. Boyle VJ, Simonet WS, Laney DL (2003) Osteoclast differentiation and activation. Nature 231: 337–342.

7. Suda T, Takahashi N, Udagawa N, Jimi E, Gillespie MT, et al. (1999) Segregation of TRAF6-mediated signaling pathways clarifies its role in osteoclastogenesis. EMBO J 20: 1271–1280.
18. Odkhuu E, Koide N, Haque A, Tsolmongyn B, Naiki Y, et al. (2012) Inhibition of tumor necrosis factor-alpha mediates orthopedic implant osteolysis. Am J Pathol 184: 1346.

25. Tsutsumi R, Hock C, Bechtold CD, Proulx ST, Bukata SV, et al. (2008) Differential effects of biologic versus bisphosphonate inhibition of wear debris-induced osteolysis assessed by longitudinal micro-CT. J Orthop Res 10: 1340–1346.

26. Childs LM, Goater JJ, O'Keefe RJ, Schwarz EM (2001) Effect of anti-tumor necrosis factor-alpha gene therapy on wear debris-induced osteolysis. J Bone Joint Surg Am 83: 1789–1797.

27. Masui T, Sakanoue Y, Warashina H, Ishiguro N (2005) Expression of inflammatory cytokines, RANKL and OPG induced by titanium, cobaltchromiummum polyethylene particles. Biomaterials 26: 1695–1702.

28. Kim K, Kim JH, Lee J, Jin HM, Lee SH, et al. (2005) Nuclear factor of activated T cells c1 induces osteoclast-associated receptor gene expression during tumor necrosis factor-related activation-induced cytokine mediated osteoclastogenesis. J Biol Chem 280: 53209–53216.

29. Mitchell AE, Jones AD, Mercer RS, Tucker KB (1999) Characterization of pyrroloquinoline quinone amino acid derivatives by electrospray ionization mass spectrometry and detection in human milk Anal. Biochem 269: 317–323.

30. Urakami T, Yoshiida C, Akaie T, Maeda H, Nishigori H, et al. (1997) Synthesis of monoesters of pyrroloquinoline quinone and imidazopyrroloquinoline, and radical scavenging activities using electron spin resonance in vitro and pharmacological activity in vivo. J Nutr 127: 19–23.

31. Hamagishi Y, Murata S, Kamei H, Oki T, Adachi O, et al. (1990) New biological properties of pyrroloquinoline quinone and its related compounds: inhibition of chemiluminescence, lipid peroxidation and rat paw edema J Pharmacol 255: 980–985.

32. Xu F, Mack CP, Quandt KS, Shlafer M, Massey V (1993) Hultquist Pyrroloquinoline quinone acts with flavin reductase to reduce feryl myoglobin in vivo protects isolated heart from re-oxygenation injury Biochem. Biophys. Res. Commun 193: 434–439.

33. Murase K, Hattori A, Kohno M, Hayashi K (2009) Stimulation of nerve growth factor synthesis/secretion in mouse astroglial cells by coenzymes J Biol Chem 284: 25209–25219.

34. Jensen FE, Gardner GJ, Williams AP, Gallop PM, Aizenman E, et al. (1994) The putative essential nutrient pyrroloquinoline quinone is neuroprotective in a rodent model of hypoxic/ischemic brain injury. Neuroscience 62: 399–406.

35. Sanchez RM, Gardner G, Orlando L, Tsan DK, et al. (2000) Novel role for the NMDA receptor redox modulatory site in the pathophysiology of seizures J Neuro 20: 2409–2417.

36. Habara N, Watanabe A, Kobayashi M, Tsuji T, Gomita Y, et al. (1988) Pyrroloquinolinequinone Inhibit Osteolysis in Mice

37. Takayanagi H, Kim S, Koga T, Ishida H, Ishimi M, et al. (2002) Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev Cell 3: 829–841.

38. Hefferan TE, Evans GL, Lotinun S (2003) Effect of gender on bone turnover in adult rats during simulated weightlessness. J Appl Physiol 95: 1775–1781.